As with other GLP-1 agonists, retatrutide is likely to be unsuitable for those with a family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2
doi:10.1155/2017/1617458 21
Mitochondria and Cancer
Understanding Semaglutide: A Game-Changer in Weight Loss Semaglutide is a GLP-1 receptor agonist, originally developed to treat type 2 diabetes by regulating blood sugar levels
As seen below, there are body wide effects that include the brain, liver, pancreas, stomach, intestine, skeletal muscle and fat tissue
For example, in nondiabetic Wistar rats, higher levels of glucose, insulin, and glucagon-like peptide 1 (GLP-1) were observed 2 hours following the ingestion (via oral gavage) of a free amino acid mixture compared to intact albumin ( vs 123.7 3.3 mg/dL